abstract: BACKGROUND: It is hypothesized that exercise can lead to a decrease in @entity0 risk through several hormonal and nonhormonal mechanisms. The WISER ( @entity1 In Steady Exercise Research) study investigated the effects of aerobic exercise on premenopausal sex hormone levels. METHODS: Three hundred ninety-one sedentary, healthy, young eumenorrheic @entity1 were randomized either into an exercise intervention of 30 minutes of aerobic exercise 5 times a week for approximately 16 weeks (n = 212) or into a control group (n = 179). Serum levels of @entity2 , @entity7 , @entity3 , and @entity5 ( @entity5 ), all in the midfollicular phase, and of @entity6 , in the midluteal phase, were measured at baseline and at the end of the 16-week period. RESULTS: Compared with the controls (n = 153), exercisers (n = 166) experienced significant @entity4 , lean body mass, and decreases in percent body fat. There were no significant changes in body weight and menstrual cycle length between or within groups. @entity6 decreased significantly in exercisers; however, this reduction was similar to that of the control group. No significant changes between or within groups were found for any of the other sex hormones or @entity5 . CONCLUSIONS: In premenopausal @entity1 , 16 weeks of 150 minutes per week of moderate aerobic exercise in young @entity1 did not significantly alter sex hormone or @entity5 levels. IMPACT: Any favorable effects that moderate aerobic exercise without an associated weight change may have on @entity0 risk in premenopausal @entity1 are unlikely to be a consequence of changes in levels of sex hormones or @entity5 .

title: Effects of aerobic exercise on premenopausal sex hormone levels: results of the WISER study, a randomized clinical trial in healthy, sedentary, eumenorrheic XXXX .

answer: @entity1


abstract: UNASSIGNED: Although @entity1 and high-mortality are frequent in high-grade @entity5 ( @entity8 ), these findings are less commonly seen in low-grade @entity8 (LGESSs), even in cases with @entity1 ( @entity1 ). We hypothesized that the "bulging plugs" of @entity2 characteristic of @entity1 in LGESS are fundamentally different from @entity1 seen in HGS. We reviewed 70 uterine @entity4 : 42 @entity8 ( @entity8 , undifferentiated @entity4 , and @entity6 ) and 28 LGESSs. All cases had @entity1 documented on the histologic slides. Immunostains for @entity7 , ERG, and D2-40 were performed. LGESS harbored cohesive intravascular @entity2 foci with direct communication from the main @entity2 and attached to the vessel wall. The intravascular foci included @entity2 cells and small arteriole-type vessels and were surrounded by a thin fibrous band. Vascular markers confirmed the @entity1 and highlighted positively stained endothelial cells separating intravascular @entity2 foci from the blood itself. In contrast, intravascular @entity2 foci in HGS were composed of discohesive cells clusters, lacking the features described in LGESS. Only 8 (30.8%) @entity0 with LGESS had recurrence/ @entity1 (6 with lung @entity1 ); only 1 @entity0 died of disease. Thirty (77%) @entity0 with HGS had recurrence/ @entity1 , 27 (69%) @entity0 had lung @entity1 , and 22 (56.4%) @entity0 died of disease. We propose that in most LGESSs, @entity1 represents vascular intrusion; manipulation or @entity3 is potentially responsible for @entity2 cell detachment into the circulation increasing the chances of recurrence/ @entity1 . Classic @entity1 features were identified in HGS. This important distinction may allow for better management of @entity0 and avoid unnecessary treatment in LGESS, reducing morbidity.

title: Vascular invasion in uterine XXXX and its significance. A multi-institutional study.

answer: @entity4


abstract: Lipases are the enzymes of choice for laundry detergent industries, owing to their @entity0 removing ability from the soiled fabric, which eventually reduces the usage of @entity5 -based chemical cleansers in the detergent formulation. In this study, a novel thermo-alkaline lipase-producing strain identified as @entity7 was isolated from the soil samples of olive oil mill. Enhanced lipase production was observed at 55 degrees C, pH 11 and after 48 h of incubation. Among the substrates tested, @entity6 (a @entity1 source), peptone (a @entity2 source) and olive oil at a concentration of 1% were suitable substrates for enhancing lipase production. @entity4 and @entity8 were suitable substrates for maximizing lipase production. The enzyme was purified to homogeneity by a single CM-Sephadex column chromatography and revealed molecular mass of 67 kDa. The enzyme (BL1) was active over a wide range of pH from 9.0 to 13.0, with an optimum at pH 11.0, exhibited maximal activity at 55 degreesC and retained more than 70% of its activity after incubation at 70 degrees C or pH 13 for 0.5 h or 24 h, respectively. The enzyme hydrolyzed both short and long-chain @entity3 at comparable rates. BL1 was studied in a preliminary evaluation for use in detergent formulation solutions. This novel lipase showed extreme stability towards non-ionic and anionic surfactants after pre-incubation for 1 h at 40 degrees C, and good stability towards oxidizing agents. Additionally, the enzyme showed excellent stability and compatibility with various commercial detergents, suggesting its potential as an additive in detergent formulations.

title: Thermostable, alkaline and detergent-tolerant lipase from a newly isolated thermophilic XXXX .

answer: @entity7


abstract: This study concerns the effects of @entity3 in tissues on the rate of development of @entity5 (Diptera: Calliphoridae) using those tissues as a food source. @entity5 is a species of @entity2 commonly found on @entity0 corpses in Europe during the early stages of decomposition and thus of forensic interest. Three @entity1 were administered 12.5, 25.0 and 50.0 mg/h of @entity6 via ear perfusion over a period of 3 h. These dosages and duration of perfusion were calculated to give tissue concentrations of @entity3 similar to those encountered in fatal @entity0 @entity4 . A fourth @entity1 was used as a control. Following administration of the drug, @entity1 were sacrificed and 400 eggs of @entity5 , all of the same age, were placed in the eyes, nostrils and mouth of each @entity1 . Developing larvae were sampled daily to determine growth rate and weight. Puparia and emerging adult flies were also sampled. Data were analyzed using analysis of variance (ANOVA) and Student's T-test. Results of this study show that an underestimation of the postmortem interval of 24 h is possible if the presence of @entity3 in tissues is not considered. This study demonstrates again the necessity of considering the possible effects of drugs in tissues on insect growth rates when estimating the postmortem interval using entomological techniques.

title: Effects of XXXX in decomposing bodies on the development of @entity5 (Diptera: Calliphoridae).

answer: @entity3


abstract: BACKGROUND: @entity8 (receptor for advanced glycation end products [AGEs]) plays a role in @entity1 . Recently, we have demonstrated enhanced expression of @entity7 and PGE synthase-1 ( @entity6 / @entity9 ) in @entity0 symptomatic plaques, and provided evidence that it is associated with metalloproteinase (MMP)-induced @entity3 . However, the specific transmembrane signaling pathway(s) influencing plaque @entity6 / @entity9 expression is unknown. The aim of this study was to characterize @entity8 expression in @entity0 plaques and to correlate it with the inflammatory infiltration, @entity6 / @entity9 and MMP expression, and with clinical evidence of @entity1 . METHODS AND RESULTS: Plaques obtained from 60 @entity0 undergoing carotid endarterectomy were divided into @entity1 and nondiabetic according to clinical evidence of type 2 @entity1 . Plaques were subjected to analysis of @entity8 , NF-kappaB, @entity6 / @entity9 , @entity4 and @entity5 , lipid and oxidized LDL (oxLDL) content, and collagen content by immunohistochemistry and Western blot, whereas zymography was used to detect MMP activity. Immunohistochemistry was used to identify CD68+ macrophages, CD3+ T-lymphocytes, smooth muscle cells (SMCs), and HLA-DR+ inflammatory cells. @entity1 had more (P<0.0001) macrophages, T-lymphocytes, and HLA-DR+ cells, more (P<0.0001) immunoreactivity for @entity8 , activated NF-kappaB, @entity6 / @entity9 , and MMPs, increased (P<0.0001) gelatinolytic activity, reduced (P<0.0001) collagen content, and @entity2 and oxLDL content. Interestingly, @entity8 , @entity6 / @entity9 , and MMP expression was linearly correlated with plasma level of HbA1c. CONCLUSIONS: In conclusion, this study demonstrates in @entity0 that @entity8 overexpression is associated with enhanced inflammatory reaction and @entity6 / @entity9 expression in @entity1 macrophages, and this effect may contribute to plaque destabilization by inducing culprit metalloproteinase expression.

title: The receptor @entity8 as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in XXXX atherosclerotic plaques: role of glycemic control.

answer: @entity0


abstract: BACKGROUND: miRNAs control important cellular functions including angiogenesis/angiostasis or @entity1 and reveal altered expression during pathological processes in the lung. METHODS: The aim of the study was to investigate the expression of selected miRNAs ( @entity9 -let7f, @entity15 , @entity12 , @entity5 , @entity10 , @entity14 , @entity13 , @entity9 -192 @entity3 , @entity7 ) in @entity0 with @entity6 (n   =   94) and controls (n   =   50). The expression was assessed by q-PCR in BALF cells and peripheral blood lymphocytes (PB lymphocytes). For statistical analysis, the Kruskal-Wallis test, Mann-Whitney U- test, Neuman-Keuls' multiple comparison test, and Spearman's rank correlation were used. RESULTS: In BALF cells, significantly higher expression of @entity11 and @entity3 and lower expression of @entity15 were found in @entity0 than controls. @entity10 , @entity11 and @entity3 expression was significantly higher in @entity0 without parenchymal involvement (stages I) than those at stages II-IV. @entity0 with @entity4 demonstrated significantly higher @entity10 , @entity11 and @entity3 expression than those with insidious onset. For PB lymphocytes, @entity0 demonstrated significantly greater @entity15 , @entity10 , @entity11 , @entity3 and @entity7 expression, but lower @entity9 -let7f and @entity13 expression, than controls. Stage I @entity0 demonstrated significantly higher @entity12 and @entity15 expression than those in stages II-IV, and @entity0 with the acute form demonstrated higher @entity13 and @entity15 expression. In BALF cells, @entity12 and @entity5 expression was significantly higher in @entity0 with lung volume restriction, and @entity9 -let7f was higher in the PB lymphocytes in @entity0 with @entity8 . Several correlations were observed between the pattern of miRNA expression, lung function parameters and selected laboratory markers. CONCLUSION: The obtained results suggest that the studied miRNAs play a role in the pathogenesis of @entity2 , and that some of them might have negative prognostic value.

title: Altered miRNA expression in XXXX .

answer: @entity6


abstract: PURPOSE: To investigate whether @entity3 ( @entity3 ) for @entity1 of the liver in central location is a sufficient and safe therapeutic option. MATERIAL AND METHODS: According to predefined criteria, 23 of 136 @entity0 were chosen to be treated with @entity3 because of @entity2 . At the time of the first @entity3 , the @entity0 had 28 central @entity1 (27 metastases, one HCC), which were treated in 34 sessions with 64 laser applications and had a clinical and imaging follow-up every 3 months. RESULTS: The primary effectiveness rate was 74.1% and the secondary effectiveness rate 82.1%. The mortality rate was 0%. Major complications occurred in one @entity0 ( @entity4 ), while minor complications occurred in 10 @entity0 . During the median follow-up of 20 months (range 3-57 months), @entity1 progression developed in 22% of the @entity1 . The effectiveness rate was 78.6%, 71.4% and 64.3% after 3, 6 and 9 months. The median survival was 46.0 months (95% confidence interval: 28.6-47.1 months). CONCLUSION: In our @entity0 , complications and ablation rate of @entity3 for central @entity2 do not differ from those in peripheral location as described in the literature.

title: [Laser-induced thermotherapy ( XXXX ) of @entity1 of the liver in central location: results and complications].

answer: @entity3


abstract: OBJECTIVE: The aim of this study was to evaluate the accuracy of intra-operative ultrasound (IOUS) imaging in detecting liver secondaries at the time of primary colorectal surgery and to evaluate the impact of IOUS on @entity0 management. METHODS: Data from 167 @entity0 with primary @entity2 who were admitted for elective surgery between January 1995 and December 2003 were prospectively evaluated and analysed. All @entity0 underwent pre-operative abdominal ultrasonography (US) and computed tomography (CT), as well as IOUS. The final diagnosis of liver @entity1 was made by means of histological examination of either biopsy or surgical specimens. The sensitivities of pre-operative US and CT were compared with the sensitivity of IOUS, referred to histology. Changes in surgical management owing to IOUS findings were noted. RESULTS: IOUS supplied additional information in the case of 31 @entity0 . In 28 of these @entity0 , this information had a major impact on the intra-operative strategy, in that the procedure was altered. CONCLUSIONS: IOUS is safe, simple to perform and more accurate than pre-operative imaging. It reduces the number of @entity0 subjected to superfluous surgery. The use of IOUS is therefore encouraged during @entity2 surgery.

title: Intra-operative ultrasound for detection of liver XXXX from @entity2 .

answer: @entity1


abstract: UNASSIGNED: Gyrification @entity1 are considered a marker of early deviations from normal developmental trajectories and a putative predictor of poor outcome in @entity2 . The aim of this study was to explore cortical folding morphology in @entity0 with @entity4 ( @entity4 ). A MRI brain study was conducted on 38 @entity0 with @entity4 , 20 fully recovered @entity0 , and 38 healthy @entity0 . Local gyrification was measured with procedures implemented in FreeSurfer. Vertex-wise comparisons were carried out to compare: (1) @entity4 @entity0 and healthy @entity0 ; (2) @entity0 with a full remission at a 3-year longitudinal follow-up assessment and @entity0 who did not recover. @entity4 @entity0 exhibited significantly lower gyrification when compared with healthy controls. @entity0 with a poor 3-year outcome had significantly lower baseline gyrification when compared to both healthy @entity0 and @entity0 with full recovery at follow-up, even after controlling for the effects of duration of illness and gray matter volume. No significant correlation has been found between gyrification, body mass index, amount of @entity3 , onset age, and duration of illness. Brain gyrification significantly predicted outcome at follow-up even after controlling for the effects of duration of illness and other clinical prognostic factors. Although the role of starvation in determining our findings cannot be excluded, our study showed that brain gyrification might be a predictor of outcome in @entity4 . Further studies are needed to understand if brain gyrification abnormalities are indices of early neurodevelopmental alterations, the consequence of starvation, or the interaction between both factors. Hum Brain Mapp, 2015.    2015 Wiley Periodicals, Inc.

title: Gyrification XXXX as predictors of outcome in @entity4 .

answer: @entity1


abstract: This study investigates the genetic association of the SNP present in the @entity3 gene with performance traits, organs and carcass of broilers to help marker-assisted selection of a paternal broiler line (TT) from EMBRAPA @entity1 and Poultry, Brazil. Genetic and phenotypic data of 1,400 broilers for 68 traits related to body performance, organ weights, weight of carcass parts, and yields as a percentage of organs and carcass parts were used. The maximum likelihood method, considering 4 analytical models, was used to analyze the genetic association between the SNP and these important economic traits. The association analysis was performed using a mixed animal model including the random effect of the animal (polygenic), and the fixed effects of sex (2 levels), hatch (5 levels) and SNP (3 levels), besides the random error. The traits significantly associated (P<0.05) with the SNP were analyzed, along with body weight at 42 days of age (BW42), by the restricted maximum likelihood method using the multi-trait animal model to estimate genetic parameters. The analysis included the residual and additive genetic random effects and the sex-hatch fixed effect. The additive effects of the @entity2 were associated with breast meat (BMY), @entity0 ( @entity0 ), body weight at 35 days of age (BW35); drumstick skin (DSW), drumstick (DW) and breast (BW) weights. The heritability estimates for these traits, in addition to BW42, ranged from 0.24  0.06 to 0.45  0.08 for @entity0 and BW35, respectively. The genetic correlation ranged from 0.02  0.18 for @entity0 and BMY to 0.97  0.01 for BW35 and BW42. Based on the results of this study, it can be concluded that @entity3 gene is associated with performance traits BW35, LIV and BMY, DW, BW and DW adjusted for body weight at 42 days of age. Therefore, the @entity3 gene is an important molecular marker that could be used together with others already described to increase the economically important traits in broilers.

title: Association between XXXX candidate gene and performance, organs and carcass traits in broilers.

answer: @entity3


abstract: Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of @entity5 , @entity7 , @entity6 and @entity0 / @entity2 (AMC) between 2007 and 2010 in the in-and outpatient healthcare setting in 10 European countries provided by IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consumption was expressed in defined @entity4 ( @entity4 ). We analysed the number of prescriptions by diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD-10). These ICD-10 codes were grouped into four main categories: @entity3 , @entity1 , other @entity1 and other diagnoses. In 2010, the consumption of @entity5 and @entity7 ranged from 0.45 @entity4 (Sweden) to 5.46 @entity4 (Italy), and from 0.04 @entity4 (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively in the hospital setting. The consumption of AMC ranged from <0.001 @entity4 (Norway) to 11.67 @entity4 (Spain). During the study period, the consumption of @entity5 decreased, the consumption of AMC increased in most of European countries, and @entity7 varied very slightly. @entity5 and AMC were mainly prescribed for @entity3 in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly related with an @entity1 . @entity7 were prescribed for the @entity3 and other @entity1 groups. There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories. The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.

title: Sales of @entity5 , @entity7 , streptogramins, and @entity0 / XXXX in the in- and outpatient setting in 10 European countries, 2007-2010.

answer: @entity2


abstract: Introduction. The aim of this study was to evaluate the role of auriculotherapy with mustard seeds in the treatment of @entity3 ( @entity4 ), @entity0 , and electromyographic (EMG) activity in university students. Methodology. The State Trait @entity0 Inventory (STAI), Research Diagnostic Criteria (RDC) for @entity4 ( @entity4 ), and electromyography were used in this study of 44 college students with high levels of @entity0 and @entity4 . The subjects were divided into two groups: an auriculotherapy (AA) group (n = 31) and an AA sham group (n = 13). The mustard seeds were applied to the shenmen, rim, sympathetic, brain stem, and @entity2 ( @entity2 ) points in the AA group and to sham points in the external ear and wrist in the AA sham group. The treatment protocol was 10 sessions (two treatments per week). Results. @entity0 (p < 0.01) was significantly reduced in the AA group. This group also showed a decrease in tender points in the mandibular posterior region (p = 0.04) and in the right side of the submandibular region (p = 0.02). Complaints of @entity1 were reduced in the temporal tendon (p  <= 0.01) and in the left side of the ATM (p < 0.01). In addition, electromyographic (EMG) activity was reduced during temporal muscle contraction (p = 0.03).      Conclusion. Auriculotherapy was effective in the treatment of students with @entity0 and @entity4 .

title: Role of Auriculotherapy in the Treatment of XXXX with @entity0 in University Students.

answer: @entity3


abstract: We review the progress in testing the thrifty phenotype hypothesis. Many @entity0 epidemiological studies both by ourselves and others have confirmed and extended the original observations on which the hypothesis was based. We are not aware of any contradictory findings and we emphasise the strength of the association between birth weight and the subsequent development of the @entity5 . We have worked extensively experimentally to test the hypothesis in a @entity2 model in which pregnant and/or lactating dams are fed a diet moderately restricted in proteins. The range of programming effects that we have discovered in this example of fetal and early postnatal growth restriction is listed and includes changes in hormone receptors, signalling molecules and regulatory enzymes. We have shown the model to develop @entity1 , the @entity5 and signs of @entity4 . We summarise these and other similarities between the phenotype of this model and @entity0 @entity6 . The number of insults during early development which can lead to a similar outcome is discussed and the suggestion is made that the early life response to stress is limited in its flexibility with outcomes including ageing and decreased longevity. Our preliminary results indicate that some MODY genes could suggest pathways whereby the changes occur and that epigenetic changes during development are involved. We conclude that the way is now clear to discover early @entity0 markers of programming by early life growth restriction and to use these to devise strategies for the prevention of @entity3 2 @entity1 .

title: For debate: Fetal and early postnatal growth restriction lead to XXXX , the @entity5 and @entity4 .

answer: @entity1


abstract: AIM: The goal of this study was to specifically address the incidence of dorsal leakage when performing vertebroplasty in @entity0 with posterior wall @entity7 or @entity4 , by using a delayed injection of cement with the aim of increasing its viscosity. MATERIALS AND METHODS: We prospectively reviewed the records of 24 @entity0 (13 @entity0 , 11 @entity0 ; age range 42-67  years; mean age 54.7) with diagnosis of @entity5 ( @entity5 ) who underwent 34 vertebroplasties between January 2007 and January 2010 for @entity3 osteolytic localization of @entity5 with dorsal cortical @entity7 or @entity4 . All vertebroplasties were performed with an 8  min delay, which was half of the allotted injecting time given for the chosen cement. In 11 cases there were @entity4 involving the posterior wall, in 1 case with @entity6 , and in 33 cases there was dorsal cortical @entity7 . All of the @entity0 showed no response to standard treatments such as radiotherapy, chemotherapy, and analgesic treatments. RESULTS: Technical success was achieved in all cases. In 20 @entity0 , we treated only one high-risk @entity2 , in six @entity0 we treated two segments, and in one @entity0 we treated three segments. All @entity0 experienced improvement in symptoms after the procedure as demonstrated by improved visual analogue scores (VAS) and performance status (PS) and decreased doses of analgesic. There was a dorsal leakage in 2/34 (5.8%) treated vertebral bodies in which an epidural space @entity1 extension was also diagnosed, without increasing neurological symptoms after the intervention. CONCLUSION: From these results vertebroplasty with delayed injection of cement is safe and effective in the treatment of vertebral localization of @entity5 with @entity7 or @entity4 of the posterior vertebral wall.

title: XXXX with @entity7 or @entity4 of the posterior vertebral wall. Usefulness of a delayed cement injection.

answer: @entity5


abstract: BACKGROUND: A @entity4 / @entity5 ( @entity7 ) substitution occurring in position -174 of the @entity3 ( @entity3 ) gene promoter changes the expression of @entity3 circulating proteins. We evaluated the occurrence of @entity3 @entity6 polymorphism in @entity0 with acute @entity2 and studied its association with @entity1 severity, outcome, and mortality. METHODS: One hundred @entity0 with acute @entity2 and 120 age and sex-matched healthy controls were studied. Genotyping was performed using polymerase chain reaction and restriction enzyme analysis. Serum levels of @entity3 were measured using enzyme-linked immunosorbent assay. @entity1 was classified using Trial of @entity8 in Acute @entity1 Treatment (TOAST) classification. Severity was assessed by the National Institutes of Health @entity1 Scale. Outcome measures included modified Rankin Scale (mRS) and Barthel Index (BI) scores at 7 days and 3 and 6 months. Mortality/survival was assessed using the Kaplan-Meier analysis. RESULTS: The frequency of GG, GC, and CC genotypes did not differ significantly between cases and controls. No association was seen between TOAST subtype and genotype. At the time of admission, @entity1 was more severe in @entity0 with the GC genotype (P = .03) and less severe in the GG genotype (P = .04). The GC genotype was also associated with higher serum @entity3 levels and poor short-term (BI P = .001; mRS P = .003) and long-term outcomes (BI P = 9   10(-5); mRS P = 9   10(-5)), while the GG genotype had significantly lower serum @entity3 levels and better short and long-term outcomes (BI P = 3   10(-5); mRS P = 2   10(-4)). There was significantly lesser mortality in the GG genotype and more in the GC genotype based on the Kaplan-Meier analysis. CONCLUSIONS: @entity0 with the GC genotype had more severe @entity1 with poorer short and long-term outcomes and increased mortality. The GG genotype was associated with less severe @entity1 , better short and long-term prognosis, and survival. The GG genotype appears to be protective against @entity1 severity, outcome, and mortality.

title: @entity3 gene XXXX promoter polymorphism predicts severity and outcome in acute @entity2 @entity0 from north India.

answer: @entity6


abstract: BACKGROUND: @entity4 is a condition in which neuromuscular transmission is affected by antibodies against @entity5 components ( @entity7 , MG; and @entity10 gravis, NMG) or by defects in genes for @entity5 proteins ( @entity9 , CMSs). Clinically, some individuals seem to benefit from treatment with @entity8 , but its effects and adverse effects have not been systematically evaluated. OBJECTIVES: To assess the effects and adverse effects of @entity8 in @entity0 with @entity3 , transient neonatal MG, and the @entity9 . SEARCH METHODS: On 17 November 2014, we searched the Cochrane @entity6 Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE. We also searched reference lists of articles, conference proceedings of relevant conferences, and prospective trial registers. In addition, we contacted manufacturers and researchers in the field. SELECTION CRITERIA: We considered randomised controlled trials (RCTs) and quasi-RCTs comparing @entity8 as a single or add-on treatment with any other active treatment, placebo, or no treatment in adults or @entity0 with @entity3 , NMG, or CMSs. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed study design and quality, and extracted data. We contacted study authors for additional information. We collected information on adverse effects from included articles, and contacted authors. MAIN RESULTS: We found no RCTs or quasi-RCTs, and therefore could not establish the effect of @entity8 on MG, NMG and CMSs. We describe the results of 53 non-randomised studies narratively in the Discussion section, including observations of endurance, muscle strength and quality of life. Effects may differ depending on the type of @entity4 . Thirty-seven studies were in @entity0 with CMS, five in @entity0 with MG, and in 11 the precise form of @entity4 was unknown. We found no studies for NMG. Reported adverse effects included @entity2 , @entity1 , nervousness, and withdrawal symptoms. AUTHORS' CONCLUSIONS: There was no evidence available from RCTs or quasi-RCTs, but some observations from non-randomised studies are available. There is a need for more evidence from suitable forms of prospective RCTs, such as series of n-of-one RCTs, that use appropriate and validated outcome measures.

title: @entity8 for @entity4 , XXXX and the @entity9 .

answer: @entity10


abstract: The role of the lipid abnormalities as a risk factor for @entity1 remains controversial; very likely because only the standard lipid fractions are measured and because different causes of @entity1 are not considered. LDL phenotype B promotes @entity5 and is recognized as a risk factor for @entity6 , but its prevalence in @entity4 of distinct causes is unknown. Therefore we designed the study to investigate the prevalence of LDL phenotype B in @entity1 survivors with large @entity8 ( @entity8 ) and to establish the relationship between LDL phenotypes and basic lipid fractions in this group of @entity0 . 59 @entity0 (24 @entity0 with @entity2 and 35 @entity0 with @entity8 ) being at least 3 months after @entity4 were included into the study. 30 sex- and age-matched subject served as controls. The concentrations of total @entity3 , HDL- and LDL- @entity3 , as well as @entity7 were measured and the LDL phenotype was determined using the @entity9 density gradient ultracentrifugation. The LDL phenotype B was more frequent in @entity0 with @entity2 (67%, p < 0.05) compared to @entity0 with @entity8 and with controls. LDL phenotype B was also more frequent in @entity0 with @entity8 (40%) and in all @entity1 survivors combined (51%), when compared with control group (17%, p < 0.05; chi-square test). Among @entity1 survivors, controls and studied subjects as a whole, those with LDL phenotype B revealed the lower concentration of HDL- @entity3 (1.19 +/- 0.33 vs. 1.46 +/- 0.42; 1.16 +/- 0.29 vs. 1.53 +/- 0.3 and 1.19 +/- 0.32 vs. 1.49 +/- 0.37, respectively; p < 0.05, Student t-test) when compared with carriers of LDL A phenotype. The LDL phenotype B is more frequent in @entity4 compared to controls, and within the group of @entity1 survivors, @entity10 is more prevalent in @entity0 with @entity2 . The LDL phenotype B is associated with lower concentration of HDL- @entity3 .

title: [LDL phenotype A and B in XXXX ].

answer: @entity4


abstract: The objective of this study was to evaluate the effects of diet composition on phytate (InsP6) degradation in dairy @entity1 . In Experiment 1, four diets that differed in the amount and source of @entity2 (P) were fed to 24 lactating @entity1 in a 4     4 Latin Square design. The control diet (Diet C) contained 4.18  g P/kg @entity0 ( @entity0 ). Diet MP contained additional mineral P (5.11  g P/kg @entity0 ), Diet RS contained rapeseed and rapeseed meal as organic P sources (5.26  g P/kg @entity0 ) and Diet RSM contained rapeseed meal and rapeseed oil (5.04  g P/kg @entity0 ). Total P (tP) and InsP6 excretion in faeces were measured. In Experiment 2, we used a rumen simulation technique (Rusitec) to estimate ruminal disappearance of tP and InsP6 from Diets C, MP and RSM. In Experiment 1, tP concentration in faeces increased with tP intake and was highest for Diets RS and RSM. The source of supplemented P had no influence on tP digestibility, but tP digestibility was reduced for Diets MP, RS and RSM in comparison to that for Diet C. InsP6 disappearance decreased in Diet MP (85.0%) and increased in Diets RS (92.7%) and RSM (94.0%) compared to that in Diet C (90.0%). In Experiment 2, P source influenced ruminal tP disappearance (Diet MP, 78.6%; Diet RSM, 75.3%). InsP6 disappearance for Diet C (98.1%) was higher than that for Diets MP (95.6%) and RSM (94.9%). The results confirmed the high potential of ruminants to degrade InsP6, but differences in diet composition influenced InsP6 disappearance. Further studies of the site of InsP6 degradation are required to understand the relevance of InsP6 degradation for the absorption of P.

title: Effects of mineral and rapeseed @entity2 supplementation on phytate degradation in dairy XXXX .

answer: @entity1


abstract: UNASSIGNED: @entity8 ( @entity11 ) is a neurotherapeutic drug prescribed for @entity5 , @entity3 and @entity10 , including @entity0 of reproductive age. @entity11 is a well-known teratogen that produces @entity6 in many organs including the nervous system, as well as @entity4 , including @entity7 and @entity9 . In developing brain, few studies have examined @entity11 effects on glial cells, particularly astrocytes. To investigate effects on primary glial precursors, we developed new cell culture and in vivo models using frontal cerebral cortex of postnatal day (P2) @entity1 . In vitro, @entity11 exposure elicited dose-dependent, biphasic effects on DNA synthesis and proliferation. In vivo @entity11 (300 mg/kg) exposure from P2 to P4 increased both DNA synthesis and cell proliferation, affecting primarily astrocyte precursors, as >75% of mitotic cells expressed brain lipid-binding protein. Significantly, the consequence of early @entity11 exposure was increased astrocytes, as both @entity14 + cells and glial fibrillary acidic protein were increased in adolescent brain. Molecularly, @entity11 served as an HDAC inhibitor in vitro and in vivo, as enhanced proliferation was accompanied by increased histone acetylation whereas it elicited changes in culture in cell-cycle regulators, including @entity15 , and cyclin-dependent kinase (CDK) inhibitors, @entity13 and @entity12 . Collectively, these data suggest clinically relevant @entity11 exposures stimulate glial precursor proliferation, though at higher doses can elicit inhibition through differential regulation of CDK inhibitors. Because changes in glial cell functions are proposed as mechanisms contributing to @entity2 , these observations suggest @entity11 teratogenic actions may be mediated through changes in astrocyte generation during development. This article is protected by copyright. All rights reserved.

title: XXXX stimulates proliferation of glial precursors during cortical gliogenesis in developing @entity1 .

answer: @entity8


abstract: INTRODUCTION: African Americans have a greater incidence of @entity1 than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed- @entity5 -bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. @entity3 - @entity5 -bevacizumab and maintenance bevacizumab [PacCBev]), 10% of the @entity0 were African American. PointBreak had negative findings; PemCBev did not demonstrate superior @entity4 ( @entity4 ). MATERIALS AND METHODS: PointBreak subgroup efficacy and safety data were retrospectively analyzed: African Americans versus whites for PemCBev; PemCBev versus PacCBev in African Americans; and @entity6 versus community settings for African Americans. Hazard ratios (HRs) and P values were derived from a multivariate Cox proportional hazards model after adjusting for covariates. RESULTS: Of 939 intent-to-treat (ITT) @entity0 , 94 were African American and 805 were white. African-American enrollment was uniform across the study sites (median, 1 African American per site). In the PemCBev arm, @entity4 (HR, 1.125; P  = .525), progression-free survival (PFS) (HR, 1.229; P  = .251), response (P  = .607), and @entity2 profiles were similar in African Americans versus whites. For African Americans, @entity4 (HR, 1.375; P  = .209), PFS (HR, 0.902; P  = .670), response (P  = 1.000), and @entity2 profiles were similar in the PemCBev versus PacCBev arm. For African Americans, no significant differences were seen in @entity4 (HR, 0.661; P  = .191) or PFS (HR, 0.969; P  = .915) in @entity6 versus community practice settings. CONCLUSION: In the PemCBev arm, this exploratory analysis showed no significant differences between African Americans and whites for the efficacy outcomes or @entity2 profiles. Consistent with the ITT population negative trial result, for African Americans, the median @entity4 was not superior for either arm. For African Americans, PFS and @entity4 were similar in the  @entity6 and community settings. Additional outcomes data for African Americans should be collected in @entity1 studies.

title: Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed- @entity5 -Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus @entity3 - @entity5 -Bevacizumab Followed by  Maintenance Bevacizumab in XXXX With Stage IIIB/IV Nonsquamous Non-Small-Cell @entity1 .

answer: @entity0


abstract: PURPOSE: Higher urine @entity5 is a common feature of @entity5 @entity7 and may be associated with lower bone mineral density in individuals with @entity6 . However previous population based studies of @entity6 and the risk of @entity4 demonstrate conflicting results. We examined independent associations between a history of @entity6 and incident @entity4 . MATERIALS AND METHODS: We performed prospective studies using data from the Nurses' Health Study of 107,001 @entity0 with 32 years of followup and the Health Professionals Follow-up Study of 50,982 @entity0 with 26 years of followup. We excluded premenopausal @entity0 , @entity0 younger than 45 years and individuals who reported @entity2 at baseline. Study outcomes were incident wrist (distal radius) or incident hip (proximal femur) @entity4 due to low or moderate @entity1 . Cox proportional hazards regression was used to adjust for multiple factors, including age, race, body mass index, @entity8 use, supplemental @entity5 and dietary intakes. RESULTS: There were 4,940 wrist and 2,391 @entity3 in @entity0 , and 862 wrist and 747 @entity3 in @entity0 . All @entity4 were incident. The multivariable adjusted relative risk of incident wrist @entity4 in @entity0 with a history of  @entity6 compared to @entity0 without @entity6 was 1.18 (95%  CI  1.04-1.34) in @entity0 and 1.21 (95% CI 1.00-1.47) in @entity0 . The pooled multivariable adjusted relative risk of wrist @entity4 was 1.20 (95% CI  1.08-1.33). The multivariable adjusted relative risk of incident @entity3 in @entity0 with @entity6 was 0.96 (95% CI 0.80-1.14) in @entity0 and 0.92  (95% CI 0.74-1.14) in @entity0 . The pooled multivariable adjusted relative risk of @entity3 was 0.94 (95% CI 0.82-1.08). CONCLUSIONS: @entity7 is associated with a significantly higher risk of incident wrist but not @entity3 in @entity0 and @entity0 .

title: XXXX and Risk of Incident Bone @entity4 .

answer: @entity7


abstract: @entity1 rates between institutions and over time is only valid if standard, valid and reliable definitions are used. The aim of this review was to assess evidence of validity and reliability of the definition and measurement of surgical wound @entity0 . A systematic review was undertaken of prospective studies of surgical wound @entity0 published over a seven-year period; 1993-1999. The information extracted from individual studies included: @entity1 ; details of wound assessment scale, scoring or grading scale systems; and evidence of assessment of validity, reliability and feasibility of identified definitions and grading systems. Two independent reviewers appraised 112 prospective studies, 90 of which were eligible for inclusion; eight studies assessed validity and/or reliability. Forty-one different definitions of surgical wound @entity0 were identified, five of which were 'standard' definitions proposed by multi-disciplinary groups. Presence of pus was the most frequently used single component of any definition; the CDC definitions of 1988 and 1992 were the most widely implemented standard definitions; and the ASEPSIS wound assessment scale was the most frequently used quantitative grading tool. Only two formal validations of a definition were found, and six studies of reliability. This review highlights the extent of variation in @entity1 used in clinical practice, and the need for validation of both content and organization of a surveillance system. However, realistically, there will have to be a balance between the quality of the measurement and the practicality of surveillance.

title: The quality of measurement of surgical wound XXXX as the basis for monitoring: a systematic review.

answer: @entity0


abstract: Modification of the vestibulo-ocular reflex (VOR) by vestibular habituation is an important paradigm in the study of neural plasticity. The VOR is responsible for rotating the eyes to maintain the direction of gaze during @entity1 . The response of the VOR to @entity1 is quantified by its gain (eye rotational velocity/head rotational velocity) and phase difference (eye velocity phase--inverted head velocity phase). The frequency response of the VOR in na  ve animals has been previously modeled as a @entity4 ( @entity4 ). A @entity4 passes signals above its corner frequency with gain 1 and phase 0 but decreases gain and increases phase lead (positive phase difference) as signal frequency decreases below its corner frequency. Modification of the VOR by habituation occurs after prolonged low-frequency rotation in the dark. @entity2 causes a reduction in low-frequency VOR gain and has been simulated by increasing the corner frequency of the @entity4 model. This decreases gain not only at the habituating frequency but further decreases gain at all frequencies below the new corner frequency. It also causes phase lead to increase at all frequencies below the new corner frequency (up to some asymptotic value). We show that habituation of the @entity3 VOR is not a broad frequency phenomena but is frequency specific. A decrease in VOR gain is produced primarily at the habituating frequency, and there is an increase in phase lead at nearby higher frequencies and a decrease in phase lead at nearby lower frequencies (phase crossover). Both the phase crossover and the frequency specific gain decrease make it impossible to simulate habituation of the VOR simply by increasing the corner frequency of the @entity4 model. The simplest way to simulate our data is to subtract the output of a band-pass filter (BPF) from the output of the @entity4 model of the na  ve VOR. A BPF passes signals over a limited frequency range only. A BPF decreases gain and imparts a phase lag and lead, respectively, as frequency increases and decreases outside this range. Our model produces both the specific decrease in gain at the habituating frequency, and the phase crossover centered on the frequency of habituation. Our results suggest that VOR habituation may be similar to VOR adaptation (in which VOR modification is produced by @entity0 ) in that both are frequency-specific phenomena.

title: Analysis and modeling of frequency-specific habituation of the XXXX vestibulo-ocular reflex.

answer: @entity3


abstract: BACKGROUND: Tissue transglutaminase enzyme-linked immunosorbent assay (tTG-ELISA) has recently been proposed as a simple and fast screening test for @entity5 ( @entity5 ). The rate of false-positive and false-negative tests with tTG-ELISA, however, has not been definitively established. Therefore, the aim of our study was to investigate anti-tTG antibodies (TGA) not only in untreated @entity0 with @entity5 and in healthy controls, but also in a large group of @entity0 with other @entity3 . METHODS: The presence of TGA was investigated in sera from 111 @entity0 with untreated @entity5 , 96 @entity0 with other autoimmune conditions (28 with @entity2 , 46 with @entity6 , 10 with @entity1 , 12 with @entity7 ) and from 100 healthy controls using @entity4 tTG-ELISA (gp-TG/ELISA) and highly purified recombinant @entity0 tTG-ELISA (h-TG/ELISA). Western blotting with @entity4 tTG was also performed. RESULTS: Ninety-four @entity0 with @entity5 who tested positive for antiendomysial antibodies (AEA) and one who tested negative for AEA showed antibodies against the gp-TG. Among the controls, 50% of @entity0 with @entity2 and 6.5% of @entity0 with @entity6 tested positive with gp-TG/ELISA. Western blotting experiments revealed that the high rate of positive tests observed using ELISA among the control group sera is attributable to impurities in the gp-TG preparation. However, h-TG/ELISA tests were positive for the sera from all @entity0 who tested positive for AEA and from one control who tested negative for AEA, whereas h-TG/ELISA tests were negative for all @entity5 @entity0 who tested negative for AEA and for other controls who tested negative for AEA. CONCLUSIONS: The frequency of false-negative and false-positive tests represents the major limit to the use of gp-tTG/ELISA. However, because h-TG/ELISA is both simple and fast, it could be used in large screening programs for @entity5 .

title: Antitissue transglutaminase antibodies outside XXXX .

answer: @entity5


abstract: There is no standard treatment for recurrent @entity2 ( @entity2 ). Retreatment with @entity3 ( @entity4 ) is one treatment option. We reasoned this could be more effective if combined with a vaccine that preferentially targeted @entity4 -resistant cells. To test the feasibility and safety of such an approach, a phase 1 trial was conducted in which @entity0 with @entity2 relapsing after standard chemoradiotherapy were retreated with @entity4 in combination with a vaccine consisting of monocyte-derived dendritic cells (DC) pulsed with @entity1 cells that had previously been exposed to @entity4 in vivo in the course of primary treatment. Of 14 @entity0 , nine @entity0 completed the initial phase of priming vaccinations and two cycles of @entity4 , one proved to have radionecrosis, one rapidly progressed, and in three the yield of DC vaccine was insufficient to proceed with treatment. Other than expected toxicities related to @entity4 , there were no adverse events attributable to the combined treatment.  Two @entity0 had objective radiological responses. Six month progression-free survival was 22  %, similar to retreatment with @entity4 alone. Anti- @entity1 immune responses were assessed in peripheral blood mononuclear cells using interferon-y ELISpot, with two @entity0 meeting criteria for a vaccine-induced immune response, one of whom remained disease-free for nearly three years. Another @entity0 with an anti- @entity1 immune response at baseline that was sustained post-vaccination experienced a 12-month period of progression-free survival. In summary, the combined treatment was safe and well-tolerated but feasibility in the recurrent setting was marginal. Evidence of immune responses in a few @entity0 broadly correlated with better clinical outcome.

title: Dendritic cell vaccination combined with XXXX retreatment: results of a phase I trial in @entity0 with recurrent @entity2 .

answer: @entity3


abstract: OBJECTIVES: To determine the combination of drugs and vitamins, and their doses, for use in a single daily pill to achieve a large effect in preventing @entity2 with minimal adverse effects. The strategy was to simultaneously reduce four cardiovascular risk factors (low density lipoprotein @entity4 , blood pressure, serum @entity6 , and platelet function) regardless of pretreatment levels. DESIGN: We quantified the efficacy and adverse effects of the proposed formulation from published meta-analyses of randomised trials and cohort studies and a meta-analysis of 15 trials of low dose (50-125 mg/day) @entity3 . OUTCOME MEASURES: Proportional reduction in @entity5 ( @entity5 ) events and @entity1 ; life years gained; and prevalence of adverse effects. RESULTS: The formulation which met our objectives was: a statin (for example, @entity9 (daily dose 10 mg) or @entity10 (40 mg)); three blood pressure lowering drugs (for example, a @entity8 , a beta blocker, and an angiotensin converting enzyme inhibitor), each at half standard dose; @entity7 (0.8 mg); and @entity3 (75 mg). We estimate that the combination (which we call the Polypill) reduces @entity5 events by 88% (95% confidence interval 84% to 91%) and @entity1 by 80% (71% to 87%). One third of @entity0 taking this pill from age 55 would benefit, gaining on average about 11 years of life free from an @entity5 event or @entity1 . Summing the adverse effects of the components observed in randomised trials shows that the Polypill would cause symptoms in 8-15% of @entity0 (depending on the precise formulation). CONCLUSION: The Polypill strategy could largely prevent @entity5 and @entity1 if taken by everyone aged 55 and older and everyone with existing @entity2 . It would be acceptably safe and with widespread use would have a greater impact on the prevention of disease in the Western world than any other single intervention.

title: A strategy to reduce XXXX by more than 80%.

answer: @entity2


abstract: A 70-year-old @entity0 presented to us with the chief complaints of a generalized @entity6 and a mass in the right clavicular region that he first noticed in the year 2012. Biopsy of the mass led to the diagnosis of cutaneous nodular mass-type @entity9 ( @entity9 ) in March 2013. Phototherapy was started, and the symptoms improved temporarily. However, in late June 2013, the serum @entity4 dehydrogenase (LDH) level increased to 358 IU/L, which was 1.6 times higher than the upper limit of the reference range; based on the findings, transformation of the disease to the acute type was diagnosed. The @entity0 was treated with 6 courses of @entity8 therapy ( @entity3 , @entity2 , @entity5 , and @entity1 ), which resulted in complete remission (CR). However, the @entity6 recurred in late October 2013, and treatment with mogamulizumab was initiated. A total of 8 courses of mogamulizumab were administered, which resulted in CR. The @entity6 and cutaneous nodular masses recurred again in January 2014, and a total of 8 courses of mogamulizumab were administered again starting in February 2014. However, the @entity0 's symptoms began to worsen gradually. Phototherapy was also initiated, but had to be discontinued due to the development of photosensitivity. Treatment with the combination of mogamulizumab and @entity7 (25 mg/day for 21 days) was started in May 2014. The nodular mass rapidly decreased in size. The @entity6 or cutaneous nodular mass had not recurred as of August 2014. Thus, combined therapy with mogamulizumab plus @entity7 is considered to be effective for resolution of the cutaneous nodular masses in @entity0 with @entity9 .

title: A case of post-mogamulizumab relapse of acute-type @entity9 successfully treated with mogamulizumab and XXXX .

answer: @entity7


abstract: Breast and @entity4 in @entity6 , whether associated or not with @entity3 of the upper limb, have no functional impairment. They present an important cosmetic disgrace. Several methods for correction were proposed: muscular transfer with or without implants. Each one has its advantages and drawbacks. MATERIAL AND METHODS: We operated 20 adolescents and adults with this deformity: 13 females and 7 males. If the inferior bundle of the pectoralis major was always absent, other @entity1 such as aplasia of the latissimus dorsi may complicate the corrective procedure. The choice of the treatment depends upon the importance of the muscular and sometimes associated @entity5 , in the young @entity0 , the breast development and in both sexes the position of the nipple. RESULTS: The latissimus dorsi transfer may be considered as the most adapted technique for the pestoralis major replacement. The results are often disappointing due to the secondary muscular @entity2 . A composite implant with a part for breast reconstruction and another to fill the subclavicular gap gives satisfactory results but it has the hazards of implants.

title: [Corrective surgery of XXXX in @entity6 . General review of 20 @entity0 ].

answer: @entity4


abstract: UNASSIGNED: One of the common causes of failure in dacryocystorhinostomy for nasolacrimal duct obstruction (NLDO) is @entity1 and @entity2 around the ostium. @entity3 and @entity6 ( @entity7 ) can potentially reduce scarring by their action on the inflammatory and proliferative phase of wound healing, respectively. The purpose of this study is to evaluate the safety and efficacy of combined usage of adjunctive @entity7 and intranasal @entity8 (TA) in endonasal endoscopic dacryocystorhinostomy (EE-DCR). This is a retrospective interventional case series. All @entity0 underwent mechanical EE-DCR in two regional hospitals in Hong Kong from January 2005 to December 2006 were included. All received intraoperative @entity7 application for 5  min and gelfoam soaked with TA onto the ostium. Main outcome measures include the anatomical and functional success rate at follow-up at least 6  months after operation. Other outcomes include @entity4 occurred during and after operation. A total of 73 EE-DCR were performed in 69 @entity0 . Three @entity0 had simultaneous bilateral DCR; one had sequential DCRs for both sides. At the last follow-up, anatomical success was achieved in 68 cases (93  %) and both anatomical with functional success in 67 cases (92  %). No major complication was observed. Minor @entity4 included asymptomatic @entity1 between the nasal septum and lateral nasal wall in one @entity0 and moderate secondary @entity5 in another. EE-DCR with adjunctive @entity7 and TA is a safe and successful procedure for the treatment of NLDO.

title: Safety and efficacy of adjunctive intranasal XXXX and @entity8 in endonasal endoscopic dacryocystorhinostomy.

answer: @entity6


abstract: BACKGROUND: Viruses are the most prevalent ausative agents of @entity7 in young @entity0 . Studies have shown @entity7 in post mortem examinations during @entity5 outbreaks. The aims of this study are to assess the prevalence of and risk factors for subclinical @entity7 in young @entity0 hospitalized with an @entity4 . OBJECTIVES: Evaluation of the prevalence of asymptomatic @entity7 or decrease in heart functions during @entity5 . METHODS: A prospective study was conducted between 1st January and 30th September, 2009. The study included 45 @entity0 3-60 months old hospitalized with @entity1 with no clinical or microbiological evidence of acute @entity6 . Serum levels of troponin were obtained, and ECG and echocardiography were performed in all the @entity0 . Parameters that determined @entity7 included: (1) ECG ST-T changes suggestive of @entity7 ; (2) Increased serum troponin level; (3) Echocardiography findings including: shortening fraction less than 28%, left ventricle end diastolic diameter > than 2 standard deviations for age, abnormal @entity3 , or abnormal diastolic function. Clinical and epidemiological data were analyzed in order to determine parameters related to findings suggestive of silent @entity7 . RESULTS: In 16 (35%) @entity0 at least one parameter, and in 7 (16%) at least 2 parameters of @entity7 were found. Impaired diastolic function was found in 11 cases (69%), ECG changes in 5 @entity0 (35%, left ventricle dilatation in 4 (25%), and decreased shortening fraction in 3 cases (18%]. Other symptoms and signs of @entity7 were not found in any of the 16 @entity0 , and no clinical or epidemiological parameter was significantly associated with silent @entity7 . CONCLUSIONS: In a third of the @entity0 , some evidence of @entity2 was documented. In seven of them (16% of all cases), there were two different categories of @entity2 . Those cases are suspected to be silent @entity7 . No clinical and epidemiological parameters associated with the disease were found. The clinical importance of this phenomenon should be determined by a long-term follow-up study. SUMMARY: In this preliminary study, we found a high prevalence of cardiac involvement in hospitalised @entity0 with @entity5 . It seems that this cardiac involvement is due to acute sub-clinical @entity7 . The importance of these findings should be evaluated.

title: [THE PREVALENCE OF SUBCLINICAL MYOCARDITIS AMONG YOUNG XXXX WITH ACUTE VIRAL INFECTION].

answer: @entity0


abstract: BACKGROUND: Islet cell transplantation holds a potential cure for type 1 @entity1 , but many islet recipients do not reach long-lasting insulin independence. In this exploratory study, we investigated whether serum cytokines, chemokines and adipokines are associated with the clinical outcome of islet transplantation. METHODS: Thirteen islet transplant @entity0 were selected on basis of good graft function (reaching insulin independence) or insufficient engraftment (insulin requiring) from our cohort receiving standardized grafts and immune suppressive therapy. @entity0 reaching insulin independence were divided in those with continued (>12 months) versus transient (<6 months) insulin independence. A panel of 94 proteins including cytokines and adipokines was measured in sera taken before and at one year after transplantation using a validated multiplex immunoassay platform. RESULTS: Ninety serum proteins were detectable in concentrations varying markedly among @entity0 at either time point. Thirteen markers changed after transplantation, while another seven markers changed in a clinical subpopulation. All other markers remained unaffected after transplantation under generalized immunosuppression. Patterns of cytokines could distinguish good graft function from insufficient function including @entity2 , @entity8 , @entity6 and @entity10 before and after transplantation, by @entity12 , @entity9 , @entity4 and @entity5 only before and by @entity11 , @entity7 , @entity14 , S100A12 and sCD14 after transplantation. Three other proteins ( @entity3 , @entity13 and S100A12) associated with loss of temporary graft function before or after transplantation. CONCLUSIONS: Distinct cytokine signatures could be identified in serum that predict or associate with clinical outcome. These serum markers may help guiding @entity0 selection and choice of immunotherapy, or act as novel drug targets in islet transplantation.

title: Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 XXXX .

answer: @entity1


abstract: AIMS: In this retrospective study we assessed the predictive value of the coronary @entity4 score for significant (>50%) @entity5 relative to conventional risk factors. METHODS AND RESULTS: We investigated 5515 symptomatic @entity0 from Denmark, France, Germany, Italy, Spain and the USA. All had risk factor assessment, computed tomographic coronary angiogram (CTCA) or conventional angiography and a CT scan for coronary artery @entity4 (CAC) scoring. 1539 (27.9%) @entity0 had significant @entity5 , 5.5% of whom had zero CAC. In 5074 @entity0 , multiple binary regression showed the most important predictor of significant @entity5 to be male gender (B=1.07) followed by @entity1 (B=0.70) smoking, hypercholesterolaemia, @entity3 , family history of CAD and age but not @entity2 . When the log transformed CAC score was included, it became the most powerful predictor (B=1.25), followed by male gender (B=0.48), @entity1 , smoking, family history and age but hypercholesterolaemia and @entity3 lost significance. The CAC score is a more accurate predictor of >50% @entity5 than risk factors regardless of the means of assessment of @entity5 . The sensitivity of risk factors, CAC score and the combination for prediction of >50% @entity5 when measured by conventional angiogram was considerably higher than when assessed by CTCA but the specificity was considerably higher when assessed by CTCA. The accuracy of CTCA for predicting >50% @entity5 using the CAC score alone was higher (AUC=0.85) than using a combination of the CAC score and risk factors with conventional angiography (AUC=0.81). CONCLUSION: In symptomatic @entity0 , the CAC score is a more accurate predictor of significant @entity6 than conventional risk factors.

title: The coronary XXXX score is a more accurate predictor of significant @entity6 than conventional risk factors in symptomatic @entity0 : Euro-CCAD study.

answer: @entity4


abstract: @entity5 may render @entity4 plaques prone to rupture. To test this hypothesis, catheters with matrix-covered balloons were implanted into the aorta of @entity0 fed standard or 0. 5% @entity1 chow (n=70). In 1 month, fibrous plaques developed around the balloon. Time-dependent accumulation of @entity6 and free @entity1 was detected in the plaques of the @entity1 -fed group only. The pressure needed to rupture the plaque by balloon inflation was used as an index of plaque strength. Three months after the catheter implantation, the breaking pressure was 2.1 times lower (P<0.05) in @entity1 -fed @entity0 . It was accompanied by collagen loss, as measured by plaque @entity3 content, but not with deficiency of collagen cross-linking. Sirius red staining showed preservation of collagen originally covering the balloon and accumulation of nascent collagen in the lesions of standard chow-fed @entity0 . In the @entity1 -fed group, both mature and new collagen underwent degradation predominantly in the plaque shoulders. Collagen breakdown was associated with local accumulation of foamy macrophages. Gel zymography demonstrated relative enhancement of gelatinolytic activity at 92 and 72 kDa, as well as caseinolytic activity at 57, 45, and 19 kDa in the lipid-laden plaques. Lipid accumulation in the plaque was also associated with a loss of smooth muscle cells, the cellular source of the collagen fibers. The remaining smooth muscle cells showed increased collagen synthesis, although it was insufficient to counterbalance collagen degradation and cell loss. Thus, we have obtained direct evidence that @entity5 is accompanied by enhanced local collagen degradation, which is potentially responsible for @entity2 .

title: XXXX causes mechanical weakening of @entity0 atheroma : local collagen loss as a prerequisite of plaque rupture.

answer: @entity5


abstract: BACKGROUND: The Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) are brief cognitive screening tools that have been developed for the screening of @entity0 with Mild @entity3 . METHODS: A total of 105 @entity0 were included in this study, aged 53-89  years, with acute @entity4 admitted to hospital and fell into two groups: @entity2 @entity0 with @entity3 (SCI) and controls with no @entity3 (n-SCI). The @entity0 's characteristics are collected and regression analyses were performed to predict @entity3 . We use MMSE and MoCA assessment as prognostic indices for @entity3 of @entity0 's with @entity2 . OBJECTIVES: Our aim was to examine the effectiveness of the MMSE and MoCA in screening @entity3 . MAIN RESULTS: There were significant difference among the two groups in the prevalence of @entity1 (p < 0.05) and @entity5 (p < 0.05). A linear regression determined that the age, @entity1 , @entity5 predicted the @entity3 . The ROC results for MoCA with an AUC of 0.882 and the corresponding results for MMSE show a similar AUC of 0.839. CONCLUSION: Neuropsychological performance of @entity2 @entity0 was influenced by biological and demographic variables: age, @entity1 and @entity5 . The MoCA and MMSE are both reliable assessments for the diagnosis of @entity3 after @entity2 .

title: The use of MMSE and MoCA in @entity0 with acute XXXX in clinical.

answer: @entity4


abstract: OBJECTIVE: The objective was to determine the role of arcitumomab ( @entity4 -Scan; Immunomedics, Morris Plains, NJ), an anticarcinoembryonic antigen ( @entity4 ) @entity6 ' labeled with @entity5 , in the presurgical evaluation of @entity0 with recurrent or metastatic @entity2 . SUMMARY BACKGROUND DATA: Surgical resection is the only method known to cure recurrent or metastatic @entity2 . The location and extent of disease must be determined before surgery. The role of antibody imaging, a new @entity1 detection modality, in preoperative evaluation for resection of locally recurrent or metastatic @entity2 has not been established, either alone or in combination with standard diagnostic modalities. METHODS: In a blinded analysis of 209 @entity0 with known or suspected @entity2 , the accuracy of arcitumomab, alone and combined with computed tomography (CT), was compared to that of CT for predicting @entity1 resectability by correlating the results with surgical and histopathologic findings. RESULTS: Arcitumomab alone or combined with CT was found to be significantly more accurate for predicting surgical outcome than CT alone. When the results of CT and arcitumomab were concordant for abdominopelvic resectability, nonresectability, or absence of disease, the prediction was accurate in 67%, 100%, and 64%, respectively. Thus, the concordance for nonresectability (100% correct) may obviate the need for other diagnostic modalities or exploratory surgery. When the two tests were discordant, arcitumomab was correct substantially more often than CT. Because the liver is the most common site of distant metastasis in @entity2 , a subset of @entity0 with @entity3 was also analyzed; findings were similar to the overall resectability results. The product's safety profile was excellent: the incidence of induction of an immune response against arcitumomab was <1% and that of potentially adverse events was 1.2%. CONCLUSIONS: The accuracy of arcitumomab for assessing resectability status is greater than that of CT, both in all @entity0 undergoing evaluation for curative abdominopelvic resection of @entity2 and in the subset of @entity0 with suspected or proven liver metastases. The additional use of arcitumomab with CT potentially doubles the number of @entity0 who could be saved the cost, morbidity, and mortality of unnecessary abdominopelvic surgery and increases those who are potentially resectable for cure by 40%.

title: Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent XXXX .

answer: @entity2


abstract: INTRODUCTION: @entity3 between @entity1 ( @entity4 ) and @entity2 ( @entity2 ) is important but under-recognised. We aimed to determine the prevalence of @entity3 and the predictors of @entity4 in @entity0 with @entity2 . METHODS: @entity0 aged >=  40 years were recruited from a dedicated @entity2 clinic and underwent overnight polysomnography. A diagnosis of @entity4 was made when apnoea-hypopnoea index (AHI) was >=  5. RESULTS: In all, 22 @entity0 (aged 71    9 years), predominantly @entity0 , were recruited. Mean values recorded were: predicted forced expiratory volume in the first second percentage 55    15; body mass index 23.7    6.5 kg/m2; Epworth Sleepiness Scale score 5.6    5.8; and AHI 15.8    18.6. Among the 14 @entity0 with @entity4 (prevalence of @entity3 at 63.6%), the mean number of hospital visits for @entity2 exacerbations in the preceding one year was 0.5    0.7. @entity0 with @entity3 had worse modified Medical Research Council dyspnoea scale scores and a lower percentage of rapid eye movement (REM) sleep than @entity0 without. There were no other statistical differences in lung function or sleep study indices between the two @entity0 groups. CONCLUSION: The majority of our @entity0 had @entity3 and minimal exacerbations, and were not obese or sleepy. Significant differences between @entity0 with and without @entity3 were seen in two aspects - the former was more dyspnoeic and had less REM sleep. Our findings suggest that standard clinical predictors cannot be used for @entity0 with @entity3 , and therefore, a high index of suspicion is needed.

title: XXXX between @entity2 and @entity1 in a Southeast Asian teaching hospital.

answer: @entity3


abstract: OBJECTIVE: To explore the relationship between the @entity4 in @entity3 and ocular and systemic haemodynamic disturbance. METHODS: The color Doppler imaging was used to study blood velocity in the ophthalmic, the central retinal and the short posterior ciliary arteries in 34 @entity0 with @entity2 , 31 @entity0 with low tension @entity3 and 90 healthy controls. The peak systolic velocity(PSV), the end diastolic velocity (EDV) and resistive index (RI) in each artery were measured, moreover the nailfold microcirculation and blood viscosity in each @entity0 were examined. RESULTS: Compared with the control group, the PSV and EDV of the central retinal arteries were significantly lower while the RI of the central retinal arteries was significantly higher in both POAG and LTG @entity0 . The RI of the short posterior ciliary arteries however was significantly higher in POAG. Nailfold microcirculation shows that some important parameters, including flow pattern, loop surrounding, morphological weighted value, total weighted value and @entity1 rate in the two @entity3 groups were higher, whereas the flow velocity was lower than in the control group. The plasm viscosity and the whole blood viscosity (low spear) were higher than normal. According to our measurements, the nailfold microcirculation and blood viscosity was worse at the end stage of @entity3 than at early stage. The correlative analysis between measurement results of color doppler imaging and microcirculation and heamorrheology showed that nailfold microcirculation morphological weighted value was negatively correlated with the EDV of the central retinal artery and positively correlated with the RI of the central retinal artery in LTG @entity0 . CONCLUSIONS: The abnormity of ocular haemodynamics and systemic microcirculation and blood viscosity is one important factor of @entity4 in @entity3 .

title: [The relationship between ophthalmic nerve lesion in XXXX and ocular and systemic haemodynamic disturbance].

answer: @entity3


abstract: OBJECTIVES: To perform MRI cerebellum volumetry in @entity0 exposed to @entity4 and to identify factors associated with @entity1 ( @entity1 ). METHODS: From 100 consecutive @entity2 @entity0 we selected those with @entity4 use for more than 2 months and with MRI scan available for volumetric studies. We obtained cerebellar volumes corrected for total intracranial volume. Volumes below 2 standard deviations from the mean of control group were considered abnormal. RESULTS: We studied 56 @entity0 (33 @entity0 ). Mean age was 33.6 years and mean duration of @entity2 was 17.6 years. Mean daily dose of @entity4 was 301 mg. @entity1 was detected in 20 (35.7%) @entity0 . @entity1 was not associated with frequent generalised @entity3 . @entity1 correlated with duration of @entity2 (r=-0.34; P=0.01) and years of treatment with @entity4 (r=-0.48; P=0.001), but not with age and mean daily dosage of @entity4 (P>0.05). However, a multiple correlation analysis as well as a backward stepwise multiple regression analysis including all variables showed that only duration of treatment was significantly associated with @entity1 (P=0.001). CONCLUSIONS: @entity1 is frequently associated with long-term use of @entity4 . Although duration of @entity2 may have an influence in the @entity1 , this is clearly less important than the time of exposure to @entity4 .

title: Cerebellar volume and long-term use of XXXX .

answer: @entity4


abstract: PURPOSE: To study mortality in subjects with @entity8 ( @entity8 ), @entity6 , or @entity9 ( @entity9 ) in comparison with those without these disorders. DESIGN: Population-based prospective cohort study. @entity0 : Subjects (n = 6339) aged 55 years and older from the population-based Rotterdam Study for whom complete information on @entity11 status was present. MAIN OUTCOME MEASURES: Vital status continuously monitored from 1990 until January 1, 2000. METHODS: The diagnosis of @entity8 was made according to the International Classification System. @entity6 , determined on biomicroscopy, was defined as any sign of nuclear or (sub)cortical @entity6 , or both, in at least one eye with a visual acuity of 20/40 or less. @entity12 and @entity13 in at least one eye were classified as operated @entity6 . Definite @entity9 was defined as a @entity10 combined with a glaucomatous @entity5 . Diagnoses were assessed at baseline. Mortality hazard ratios were computed using Cox proportional hazard regression analysis, adjusted for appropriate confounders (age, gender, smoking status, body mass index, @entity4 level, @entity7 , @entity3 , history of @entity2 , and @entity1 ). RESULTS: The adjusted mortality hazard ratio for subjects with @entity14 (n = 104) was 0.94 (95% confidence interval [CI], 0.52-1.68), with biomicroscopic @entity6 (n = 951) was 0.94 (95% CI, 0.74-1.21), with surgical @entity6 (n = 298) was 1.20 (95% CI, 0.86-1.68), and with definite @entity9 (n = 44) was 0.39 (95% CI, 0.10-1.55). CONCLUSIONS: Both @entity8 and @entity6 are predictors of shorter survival because they have risk factors that also affect mortality. When adjusted for these factors, @entity8 , @entity6 , and @entity9 were themselves not significantly associated with mortality.

title: Is there a direct association between age-related XXXX and mortality? The Rotterdam Study.

answer: @entity11


abstract: BACKGROUND: The response rate of advanced or recurrent @entity2 to @entity3 (TS-1) is 46.5%, which is higher than the response rate of this type of @entity1 to any other anticancer agent. However, the incidence of adverse reactions to this drug has also been reported to be as high as 83.2%. According to a postmarketing survey, adverse reactions to this drug begin to appear 2-3 weeks after the start of drug administration. With these findings in mind, we recently devised a new dosing regimen for the drug, by which the drug is administered for 2-week periods separated by 1-week drug-free intervals (the 2-week regimen). The aim of this retrospective study was to evaluate the efficacy and feasibility of the 2-week regimen in comparison with a 4-week dosing regimen with a 2-week interval between sessions (the 4-week regimen) as the historical control. METHODS: The subjects were 27 @entity0 with advanced or recurrent @entity2 who received @entity3 therapy at our center between September 1999 and November 2001. Of these @entity0 , 14 who received the 4-week regimen before January 2001 served as historical controls, and the results in these @entity0 were compared with those of the remaining 13 @entity0 , who received the 2-week regimen after February 2001. @entity0 backgrounds, adverse reactions, compliance, and efficacy were investigated retrospectively. RESULTS: The incidence of adverse reactions tended to be lower in the 2-week-regimen group (77%) than in the 4-week-regimen group (93%). The percentage of @entity0 who received the drug for 6 months in complete compliance with the dosing schedule, as calculated by the Kaplan-Meier method, was 85% in the 2-week-regimen group and 40% in the 4-week-regimen group. The response rate to the drug was 23% in the 2-week-regimen group and 21% in the 4-week-regimen group. CONCLUSION: These results suggest that this 2-week regimen may mitigate adverse reactions and prolong the medication period.

title: A new regimen for XXXX therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.

answer: @entity3


abstract: UNASSIGNED: @entity4 ( @entity4 ), due to pro-oxidant species [reactive @entity2 species (ROS)] excess not counterbalanced by endogenous antioxidant molecules [e.g., @entity9 ( @entity12 )], is involved in the pathogenesis of @entity0 @entity1 , but few data are available on essential @entity7 (ET). This study aims to investigate @entity4 in ET off-therapy @entity0 . Thirty ET treatment-na  ve @entity0 were compared with 26 age-matched and gender-matched controls. Serum ROS, urinary @entity13 , full blood @entity12 levels, and reduced/oxidized @entity12 ratio ( @entity12 / @entity14 ) were measured. Data were adjusted for gender, age, @entity11 mutational status, smoking, @entity10 , or @entity6 requiring drug therapy, antiplatelet therapy, treatment with @entity5 , high-sensitive @entity8 levels, and absolute monocyte count. ROS and @entity12 levels were increased in both @entity0 and controls. @entity0 showed increased @entity14 (p   =   0.05), reduced @entity12 / @entity14 ratio (p   =   0.08), and similar @entity13 levels when compared with controls. No differences in @entity4 parameters were found between @entity11 -positive and @entity11 -negative @entity0 . Confounding factors did not modify the results. Our study suggests an @entity4 in a cohort of treatment-na  ve ET @entity0 , not associated with @entity11 mutational status or with chronic @entity3 situation. @entity12 / @entity14 ratio, altered in ET @entity0 because of increased @entity14 levels, showed the presence of higher @entity12 levels in ET than controls as a possible compensatory mechanism of an excess of pro-oxidant production. Copyright    2015 John Wiley _ Sons, Ltd.

title: Oxidative status in treatment-na  ve essential XXXX : a pilot study in a single center.

answer: @entity7


abstract: PURPOSE: @entity10 is an orally active aromatase inhibitor for the treatment of @entity0 . The objectives of this study were to examine the pharmacokinetic profile of @entity10 in Japanese subjects and to identify factors that influence variability in the pharmacokinetics of @entity10 using population pharmacokinetic (PPK) analysis. METHODS: Twenty-five healthy postmenopausal Japanese @entity1 were enrolled in the study and received 2.5  mg @entity10 once daily for 14 or 28  days. A PPK model was developed using NONMEM software. Age, body @entity5 ( @entity5 ), @entity13 , ALT, total @entity7 , serum @entity8 (CRE), and genotype of @entity12 were studied as covariates. @entity9 , @entity14 , and @entity3 in plasma were measured as pharmacodynamic markers. RESULTS: @entity12 genotype, CRE, and @entity13 were significant covariates for apparent systemic clearance (CL/F), and @entity5 was a significant covariate for apparent distribution volume (Vd/F). Population mean estimates of CL/F and Vd/F in subjects without @entity12 mutation were 1.03       (CRE/0.70)(-1.27)       ( @entity13 /17.5)(-0.793)   L/h and 94.2       ( @entity5 /51.1)(1.12)   L respectively. CL/F in subjects possessing 1 and 2 @entity12 mutation alleles were 84.3% and 44.8% of the value in the subjects without mutation respectively. @entity4 levels fell to below detection limits in most subjects after @entity10 administration. Three mild and transient adverse events (upper respiratory tract @entity2 , @entity11 , and @entity6 ) were reported in the study. CONCLUSIONS: @entity12 genotype largely influences CL/F of @entity10 . Genetic polymorphism of @entity12 and body @entity5 will be causes of ethnic difference in PK. However, dose adjustment is not necessary, because of the wide therapeutic range.

title: Population pharmacokinetic analysis of @entity10 in Japanese postmenopausal XXXX .

answer: @entity1


abstract: Imipenem/ @entity4 (IPM/CS) was administered to a total of 67 @entity0 with severe @entity2 complicating @entity3 and @entity1 . Fifty @entity0 are included in the present analysis of efficacy and 64 in that of safety. 1. Out of 31 @entity0 with @entity3 , responses were excellent in 10 @entity0 , good in 10 @entity0 , and the efficacy rate was 64.5%. Out of 19 @entity0 with @entity1 , responses were excellent in 8 @entity0 , good in 8 @entity0 and the efficacy rate was 84.2%. 2. For @entity0 whose responses to other antibiotics had been poor, the efficacy rate was 59.3% in the group with @entity3 and 62.5% in the group with @entity1 . 3. The relationship between the neutrophil count and efficacy was studied in the @entity0 with @entity3 . The efficacy rate for 8 @entity0 whose neutrophil counts were 500/mm3 or less was 75.0%. 4. For the @entity0 with @entity3 , the efficacy rate for @entity0 from whom causative organisms were isolated was 70.0% and that for @entity0 for whom they were unknown was 61.9%. 5. Adverse reactions were observed in 3 @entity0 and abnormal laboratory test results in 2 @entity0 . However, they were mild and disappeared after discontinuation of this drug. From these results, IPM/CS is considered to be a useful antibiotic for the treatment of severe @entity2 complicating @entity3 and @entity1 .

title: [Clinical evaluation of imipenem/ @entity4 against severe @entity2 complicating XXXX and @entity1 ].

answer: @entity3


abstract: The objective of this review was to evaluate the available medical literature concerning the electroencephalogram (EEG) during @entity2 of pregnancy. All articles found during a MEDLINE and Embase database search on the subject of EEG differences associated with @entity2 in pregnancy were screened for eligibility. In all, 22 articles which describe the EEG during @entity4 ( @entity4 )/ @entity5 were retrieved. Abnormal EEG findings were observed in the majority of the preeclamptic/eclamptic @entity0 , consisting of slow waves most frequently localized in the occipital lobe, as well as spike discharges. The EEG abnormalities in @entity4 were reversible in the majority of the cases. We conclude that these described abnormalities may be interpreted as a warning sign of deterioration of brain function in @entity4 . However, some caution regarding this conclusion is advised because most of the retrieved articles were published in the 1950s and 1960s, and were not consistent with current clinical guidelines or medical terminology. Further research is needed to establish the clinical value of implementing EEGs in the assessment of the preeclamptic/eclamptic @entity0 . TARGET AUDIENCE: Obstetricians _ Gynecologists, Neurologists, Family Physicians. LEARNING OBJECTIVES: After completion of this educational activity, the obstetrician, gynecologist and neurologist should be better able to evaluate whether the EEG is normal for pregnancy; distinguish EEG abnormalities in @entity2 in pregnancy, and assess the value of EEG @entity3 ( @entity4 )/ @entity5 for the detection of early signs of @entity1 .

title: Electroencephalography during normotensive and XXXX pregnancy: a systematic review.

answer: @entity2


abstract: BACKGROUND: Longer-term results of bioabsorbable screws for anterior cruciate ligament reconstruction (ACLR) have been reported, but results are specific to the exact screw material and design. @entity2 and @entity3 with @entity1 ( @entity4 -HA) screw outcomes have been compared only to 2 years. PURPOSE/HYPOTHESIS: The purpose of this study was to compare the clinical and radiologic outcomes of the @entity4 -HA screw versus @entity2 screw for hamstring tendon ACLR over a 5-year follow-up period. The hypothesis was that there are no differences in clinical scores or tunnel widening between the @entity4 -HA and the @entity2 screws and that the @entity4 -HA screw as seen on magnetic resonance imaging (MRI) should show high-grade resorption and ossification response over 5 years. STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: A total of 40 @entity0 undergoing ACLR were randomized to receive either a @entity4 -HA screw (PLLA-HA group) or a @entity2 screw ( @entity2 group) for ACL fixation. Blinded evaluation was performed at 2 and 5 years with the International Knee Documentation Committee and Lysholm knee score, KT-1000 arthrometer, single-legged hop test, and MRI to evaluate tunnel and screw volumes, periscrew ossification, graft integration, and cyst formation. RESULTS: There was no difference in any clinical outcome measure at 2- or 5-year follow-up between the 2 groups. At 2 years, the femoral tunnel in the @entity4 -HA group was smaller than that in the @entity2 group (P = .02); at 5 years, there was no difference. At 2 years, the femoral @entity4 -HA screw was a mean 76% of its original volume, and by 5 years, it was 36%. At 2 years, the tibial @entity4 -HA screw mean volume was 68% of its original volume, and by 5 years, it was 46%. At 5 years in the @entity4 -HA group, 88% of femoral tunnels and 56% of tibial tunnels demonstrated a significant ossification response. There was no increase in cyst formation in the @entity4 -HA group and no screw breakages. CONCLUSION: There were equivalent clinical results between the @entity4 -HA and @entity2 groups at 2- and 5-year follow-ups. The @entity4 -HA screw was not associated with increased tunnel widening or cyst formation when compared with the @entity2 screw. The @entity4 -HA screw demonstrated progressive screw resorption and gradual but incomplete ossification over 5 years.

title: Bioabsorbable Versus XXXX Screws in Anterior Cruciate Ligament Reconstruction Using Hamstring Autograft: A Prospective, Blinded, Randomized Controlled Trial With 5-Year Follow-up.

answer: @entity2


abstract: BACKGROUND AND OBJECTIVES: Neovascular @entity2 ( @entity2 ) is a chronic and @entity1 . Current treatment options are limited and have shown to slow disease progression. The aim of this study was to assess Ranibizumab effectiveness and safety and to describe @entity0 ' demographic and clinical characteristics. @entity0 AND METHOD: We conducted a retrospective observational study including all @entity0 who had started treatment between 1/12/2006 and 31/12/2008, and were followed up until 31/03/2009. A bivariate analysis on months 4, 12 and 18 and two logistic regression models were performed to analyze the influence of demographic and clinical factors on the effectiveness and durability of treatment. Adverse reactions were collected as described in the medical records to assess safety. RESULTS: A total of 126 eyes of 112 @entity0 were recruited. The mean age was 77.7 (   6.0) years. The mean durability of treatment was 18.2 months, and it was higher in the group of @entity0 who started treatment with visual acuity (VA) > 0.1 (p<0.001). Ranibizumab therapy maintained AV over baseline at 18 months. None of the studied variables showed any influence on treatment effectiveness. However, baseline visual acuity influenced on treatment duration, being higher in the group of @entity0 with AV > 0.1. CONCLUSIONS: Ranibizumab was shown to be effective until 18 months. Early diagnosis of @entity3 could lead to an earlier treatment start, when @entity0 present a higher AV, in order to optimize the benefits of treatment. Ranibizumab was well tolerated and safe in most @entity0 .

title: [Assessment of the effectiveness and safety of ranibizumab in neovascular age-related XXXX ].

answer: @entity2


abstract: OBJECTIVES: This study was conducted to determine clinical and histologic factors that would predict nodal @entity1 in @entity0 with major @entity2 . METHODS: A retrospective study of 40 @entity0 who underwent surgery, including neck dissection, for major @entity2 between 1975 and 1997 was performed. @entity0 charts were reviewed, and clinical and pathologic data were extracted along with outcome. Predictive factors were identified and survival curves were obtained. RESULTS: Neck dissections were performed in 40 @entity0 , which revealed histologic evidence of @entity2 in lymph nodes in 15 cases. Histologically proven @entity1 was found in 16% of specimens from elective and 73% of specimens from therapeutic neck dissection. Five-year overall and locoregional disease-free survival rates for histologically positive and negative groups were 40% versus 63% (P < 0.05) and 67% versus 69% (P = 0.59), respectively. Univariate analysis of the factors revealed that clinical evidence of nodal @entity1 (P < 0.001) and high-grade @entity2 (P < 0.033) predicted histologic nodal involvement. Multivariate analysis revealed that only a positive neck examination was a significant predictive factor (OR = 31, 95%CI = 2.99-312). CONCLUSIONS: Our results suggest that clinical neck examination is a reliable predictor of regional @entity1 in @entity0 with major @entity2 . In view of the low frequency of occult metastases, routine elective treatment of the neck is not recommended.

title: Predictors of nodal @entity1 in XXXX .

answer: @entity2


abstract: UNASSIGNED: @entity5 ( @entity5 ) is a well-known complication of @entity6 -based chemotherapy; however, its impact on long-term @entity0 survival is unclear. We sought to determine the incidence and risk factors for development of @entity6 -associated @entity5 and its impact on long-term renal function and @entity0 survival. We identified 233 @entity0 who received 629 cycles of high-dose @entity6 (99  9mg/m2) for treatment of @entity2 between 2005 and 2011. These subjects were reviewed for development of @entity5 . @entity6 nephrotoxicity (CN) was defined as persistent rise in serum @entity9 , with a concomitant decline in serum @entity10 and @entity8 , in absence of use of nephrotoxic agents and not reversed with hydration. All @entity0 were hydrated per protocol and none had baseline glomerular filtration rate (GFR) via CKD-EPI<60mL/min/1.73m2. The @entity0 were grouped based on development of @entity5 and were staged for levels of injury, per KDIGO- @entity5 definition. Renal function was assessed via serum @entity9 and estimated glomerular filtration rate (eGFR) via CKD-EPI at baseline, 6- and 12-months. @entity0 with @entity5 were screened for the absence of nephrotoxic medication use and a temporal decline in serum @entity8 and @entity10 levels. @entity11 models were constructed to determine risk factors for @entity6 -associated @entity5 . @entity3 was compared among groups using ANOVA. Kaplan-Maier curves and Cox proportional hazard models were constructed to study its impact on @entity0 survival. Of 233 @entity0 , 158(68%) developed @entity5 ; 77 (49%) developed stage I, 55 (35%) developed stage II, and 26 (16%) developed stage III @entity5 . Their serum @entity8 and @entity10 levels correlated negatively with level of injury (p<0.05). African American race was a significant risk factor for @entity6 -associated @entity5 , OR 2.8 (95% CI 1.3 to 6.3) and 2.8 (95% CI 1.2 to 6.7) @entity0 with stage III @entity5 had the lowest eGFR value at 12 months (p = 0.05) and long-term @entity0 survival (HR 2.1; p<0.01) than @entity0 with no or lower grades of @entity5 . Most common causes of @entity4 were recurrent @entity1 (44%) or secondary malignancy elsewhere (40%). @entity6 -associated severe @entity5 occurs in 20% of the @entity0 and has a negative impact on long-term renal function and @entity0 survival. @entity7 tube placement may be protective and should be considered in high risk- @entity0 .

title: Understanding the Risk Factors and Long-Term Consequences of @entity6 -Associated XXXX : An Observational Cohort Study.

answer: @entity5


abstract: PURPOSE: Assessment of the long-term results achieved with use of nasolacrimal stents in the treatment of @entity1 caused by obstruction of the lacrimal apparatus. The role of stents in treating this condition is evaluated. MATERIALS AND METHODS: From February 1997 to April 1999, a total of 89 procedures to insert nasolacrimal stents were performed in 77 @entity0 (20 @entity0 , 57 @entity0 ; mean age, 53 years). A total of 79 stents were successfully implanted, with 10 failures (11.2%). Postprocedural course was followed for 16-38 months (mean, 27 mo) by means of clinical examinations and/or periodic dacryocystography, with removal of occluded stents. On conclusion of the study in September 2000, dacryocystography was performed in all @entity0 in whom stents were still in place. RESULTS: Of the 79 stents deployed, two were lost, two had to be excluded from the study, 45 (60%) ceased to function, and 30 (40%) remained patent. Median duration of stent patency of these 79 stents was 20 months. Mean time to occlusion was 9.2 months for all obstructed stents; 4.4 months for improperly placed stents (via a trajectory outside the normal lacrimal drainage apparatus) and 12.2 months for stents that appeared to have been inserted properly. Of the 45 occluded stents, 40 were removed and five were left in place. Upon removal, adherence of the stents to the lacrimal apparatus was frequently observed. CONCLUSIONS: The low patency rate and the difficulties encountered in removing nasolacrimal stents during the course of long-term placement calls into question the efficacy of this method as a definitive treatment for @entity1 caused by obstruction of the lacrimal drainage system, although studies comparing this and other treatment modalities are needed. Assessment of temporary stent placement may be in order.

title: Nasolacrimal stents in the treatment of XXXX : long-term results.

answer: @entity1


abstract: An array of 13 biochemically well defined molecular forms of @entity2 , @entity0 and newly cloned @entity5 ( @entity5 ) AChEs (acetylcholinesterases) differing in glycosylation and subunit assembly status were subjected to comparative pharmacokinetic studies in @entity1 and @entity5 . The circulatory lifetimes of recombinant @entity2 , macaque and @entity0 AChEs in @entity1 were governed by previously determined hierarchical rules; the longest circulatory residence time was obtained when @entity6 was fully sialylated and tetramerized [Kronman, Chitlaru, Elhanany, Velan and Shafferman (2000) J. Biol. Chem. 275, 29488-29502; Chitlaru, Kronman, Velan and Shafferman (2001) Biochem. J. 354, 613-625]. In @entity5 , @entity2 molecular forms still obeyed the same hierarchical rules, whereas primate AChEs showed significant deviation from this behaviour. Residence times of @entity0 and rhesus AChEs were effectively extended by extensive sialylation, but subunit tetramerization and N-glycan addition had a marginal effect on their circulatory longevity in macaques. It appears that the major factor responsible for the differential pharmacokinetics of @entity2 and primate AChEs in macaques is related to differences in primary structure, suggesting the existence of a specific mechanism for the circulatory clearance of primate AChEs in @entity5 . The 35 @entity4 that differ between @entity2 and primate AChEs are clustered within three defined domains, all located at the enzyme surface, and may therefore mediate the facilitated removal of primate cholinesterases specifically from the circulation of monkeys. These surface domains can be effectively masked by @entity3 appendage, resulting in the generation of chemically modified @entity0 and macaque AChEs that reside in the circulation for extraordinarily long periods of time (mean residence time of 10000 min). This extended residence time is similar to that displayed by native macaque butyrylcholinesterase (9950 min), which is the prevalent @entity7 form in the circulation of adult macaques.

title: Amino acid domains control the circulatory residence time of primate acetylcholinesterases in XXXX ( @entity5 ).

answer: @entity5


abstract: OBJECTIVE: The aim of this study is to present our initial experience in @entity4 treatment and the technical details of @entity6 ( @entity6 ) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the light of current literature. MATERIAL AND METHODS: Data of 27 consecutive @entity0 who were treated with @entity6 and @entity4 in Medical Park Samsun Hospital, between November 2012 and September 2014 were retrospectively reviewed. Treatment indication and management were evaluated at the multidisciplinary oncology council. All @entity0 underwent @entity6 and HIPEC with the aim of complete cytoreduction. @entity0 with unresectable disease and/or palliative surgery were excluded from analysis. Perioperative complications were classified according to Clavien-Dindo classification, and HIPEC-related side effects were identified using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) criteria. Demographic, clinical and histopathological data of the @entity0 were analyzed. RESULTS: The mean age was 54 (32-72). Nineteen @entity0 were female. The origin of @entity4 was @entity1 in 12 @entity0 , @entity2 in 12 @entity0 , @entity5 in 2 @entity0 and @entity7 in 1 @entity0 . The mean @entity4 Index was 12 (3-32), with a mean operative time of 420 (300-660) minutes. Perioperative morbidity, HIPEC-related @entity3 and perioperative mortality were observed in eight (30%), one (3.7%) and four @entity0 (14.8%), respectively. During a mean follow up of 13 (1-22) months, overall and disease-free survival rates were 95.8% and 82.6%, respectively. Two @entity0 with @entity1 (after 9 and 12 months) and one @entity0 with @entity2 (after 11 months) had intra-abdominal recurrence. One @entity0 with @entity2 had liver metastases 13 months after surgery, and underwent resection of segments 6-7. The remaining @entity0 are being followed-up without any recurrence. CONCLUSION: Cytoreductive surgery and HIPEC have favorable results in the treatment of @entity0 with @entity4 . Compatible with the literature, surgical outcomes of the presented series are encouraging for this treatment modality that have been recently popularized in our country. Careful perioperative evaluation, proper @entity0 selection and multidisciplinary approach are essential for success in curative treatment of @entity4 .

title: Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of XXXX : Our initial experience and technical details.

answer: @entity4